The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2022 | Combining immunotherapy and chemotherapy in rectal cancer
Ali Shamseddine, MD, American University of Beirut, Beirut, Lebanon, explains how there are many Phase II trials investigating the use of immunotherapy with chemotherapy in patients with rectal cancer but there is currently no method of selection for patients who will benefit from this combination. This interview took place at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium 2022
